Fibrinolysis components and angiogenesis regulation by example of burn-induced corneal neovascularization in rabbits

• Published in: Vestnik oftal'mologii Vol. 128; no. 4; p. 62
• Main Authors: Chesnokova, N B, Aĭsina, R B, Mukhametova, L I, Pavlenko, T A, Gulin, D A, Beznos, O V
• Format: Journal Article
• Language: Russian
• Published: Russia (Federation) 01.07.2012
• Subjects: Angiogenesis Inhibitors - administration & dosage; Angiogenesis Inhibitors - metabolism; Angiogenesis Inhibitors - pharmacology; Angiostatins - administration & dosage; Angiostatins - metabolism; Angiostatins - pharmacology; Animals; Aqueous Humor - metabolism; Conjunctiva - metabolism; Cornea - blood supply; Cornea - metabolism; Cornea - physiopathology; Corneal Neovascularization - etiology; Corneal Neovascularization - metabolism; Corneal Neovascularization - physiopathology; Corneal Ulcer - drug therapy; Corneal Ulcer - etiology; Corneal Ulcer - metabolism; Corneal Ulcer - physiopathology; Drug Discovery; Eye Burns - chemically induced; Eye Burns - complications; Eye Burns - physiopathology; Models, Animal; Neovascularization, Pathologic - etiology; Neovascularization, Pathologic - metabolism; Neovascularization, Pathologic - physiopathology; Plasminogen - metabolism; Rabbits; Regional Blood Flow - drug effects
• ISSN: 0042-465X

Increased plasminogen level in tear fluid was found within 28 days and increased plasmin activity in 1-3 and 21 days after alkali burn of cornea, this is the time of cornel ulcers development. Increased plasminogen level and plasmin activity in cornea, conjunctiva and intraocular fluid was found in three days after trauma. Subconjunctival injections of angiostatin K1-4,5 (a product of plasminogen metabolism) during 3 weeks resulted in significant suppression of corneal neovascularization within 14 days and of active branching of the vessels in the following. The use of angiostatin reduced depth and area of corneal ulcers. Obtained data shows the promising potential of development of medications based on angiostatin K1-4,5 for suppression of corneal neovascularization and for treatment of diseases associated with corneal ulceration.